Tenalisib

• CAT Number: I009750
• CAS Number: 1639417-53-0
• Molecular Formula: C23H18FN5O2
• Molecular Weight: 415.43
• Purity: ≥95%
• Synonyms: RP6530; RP6530; RP 6530; Tenalisib.;(S)-2-(1-((7H-purin-6-yl)amino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one
• Target: PI3K
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• Related CAS: 1693773-94-2
• IUPAC Name: 3-(3-fluorophenyl)-2-[(1S)-1-(7H-purin-6-ylamino)propyl]chromen-4-one
• InChI: InChI=1S/C23H18FN5O2/c1-2-16(29-23-19-22(26-11-25-19)27-12-28-23)21-18(13-6-5-7-14(24)10-13)20(30)15-8-3-4-9-17(15)31-21/h3-12,16H,2H2,1H3,(H2,25,26,27,28,29)/t16-/m0/s1
• InChIKey: HDXDQPRPFRKGKZ-INIZCTEOSA-N
• SMILES: O=C1C(C2=CC=CC(F)=C2)=C([C@@H](NC3=C4NC=NC4=NC=N3)CC)OC5=C1C=CC=C5

Tenalisib(CAT: I009750) is a potent, dual-selective inhibitor of PI3K δ and γ isoforms, key enzymes involved in the PI3K/AKT/mTOR signaling pathway. By inhibiting these isoforms, Tenalisib modulates immune cell activity, reduces pro-inflammatory cytokine production, and impairs tumor cell proliferation and survival. This mechanism makes it highly relevant in oncology and immunology research, particularly for studying hematologic malignancies, autoimmune disorders, and chronic inflammatory conditions. Tenalisib has shown promise in preclinical and clinical settings, demonstrating anti-tumor activity and immunomodulatory effects, positioning it as a potential therapeutic agent for cancers and immune-related diseases.